Abstract
Based on more than 50 years of intensive research, we have come to the understanding that the ability of a host to reject an established tumor lesion depends on whether a cellular antitumor immune response can be effectively generated and maintained in that individual (1–5). Murine tumor models readily demonstrated, that with few exceptions, the ability to confer protective antitumor immunity to naive mice is associated with the adoptive transfer of immune lymphocytes (6–10). In marked contrast, the adoptive transfer of serum from tumor-immune animals into naive mice failed to confer resistance to tumor progression (10,11). The critical nature of cellular antitumor immunity in the prevention and treatment of human malignancy has also been substantiated.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Foley EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin, Cancer Res., 13 (1953) 835–839.
Prehn RT and Main JM. Immunity to methylcholanthrene-induced sarcomas, J. Natl. Cancer Inst., 18 (1957) 769–772.
Rosenberg SA, Spiess P, and Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes, Science, 233 (1986) 1318–1321.
Melief CJM. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes, Adv. Cancer Res., 58 (1992) 143–175.
Melief CJM and Kast WM. Lessons from T cell responses to virus induced tumours for cancer eradication in general, Cancer Surv. 13 (1992) 81–99.
Kast WM, Offringa R, Peters PJ, Voordouw AC, Meleon RH, van der Eb AJ, and Melief CJ. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes, Cell, 59 (1989) 603–614.
Barth RJ Jr, Bock SN, Mule JJ, and Rosenberg SA. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes, J. Immunol., 144 (1990) 1531–1537.
Barth RJ Jr, Mule JJ, Spiess PJ, and Rosenberg SA. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes, J. Exp. Med., 173 (1991) 647–658.
Lotze MT, Zitvogel L, Campbell R, Robbins PD, Elder E, Haluszczak C, et al. Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials, Ann. NY Acad. Sci., 795 (1996) 440–454.
Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, and Storkus WJ. Therapy of murine tumors with tumor peptide pulsed dendritic cells: dependence on T-cells, B7 costimulation, and Th1-associated cytokines, J. Exp. Med., 183 (1996) 87–98.
Roth JA (ed.) Monoclonal antibodies in cancer. Advances in diagnosis and treatment, Futura, Mount Kisco, New York, 1986.
Kliem V, Kolditz M, Behrend M, Ehlerding G, Pichlmayr R, Koch KM, and Brunkhorst R. Risk of renal cell carcinoma after kidney transplantation, Clin. Tranplant., 11 (1997) 255–258.
Ishikawa N, Tanabe K, Tokumoto T, Koga S, Okuda H, Nakazawa H, et al. Renal cell carcinoma of native kidneys in renal transplant recipients, Transplant. Proc., 30 (1998) 3156–3158.
Kunische-Hoppe M, Hoppe M, Bohle RM, Rauber K, Weimar B, Friemann S, et al. Metastatic RCC arising in a transplant kidney, Eur. Radiol., 8 (1998) 441–443.
Van den Hove LE, Van Gool SW, Van Poppel H, Baert L, Coorrevits L, van Damme B, and Ceupens JL. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumor-infiltrating T lymphocytes in human renal cell carcinoma, Clin. Exp. Immunol., 109 (1997) 501–509.
Mitropoulos D, Koui S, Rodriguez-Villanueva J, and Platsoucas CD. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma, Clin. Exp. Immunol., 97 (1994) 321–327.
Finke JH, Rayman P, Hart L, Alexander JP, Edinger MG, Tubbs RR, et al. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity interferon-y secretion and proliferation, J. Immunther. Emphasis Tumor Immunol., 15 (1994) 91–104.
Puisieux I, Bain C, Merrouche Y, Malacher P, Kourilsky P, Even J, and Favrot M. Restriction of the T-cell repertoire in tumor-infiltrating lymphocytes from nine patients with renal-cell carcinoma. Relevance of the CDR3 length analysis for the identification of in situ clonal T-cell expansions, Int. J. Cancer, 66 (1996) 201–208.
Caignard A, Guillard M, Gaudin M, Escudier B, Treibel F, and Dietrich PY. In situ demonstration of renal-cell-carcinoma-specific T-cell clones, Int. J. Cancer, 66 (1996) 564–570.
Angevin E, Kremer F, Gaudin C, Hercend T, and Triebel F. Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern clonal T-cell expansion and tumor-specific cytotoxicity, Int. J. Cancer, 72 (1997) 431–440.
Kowalczyk D, Skorupski W, Kwias Z, and Nowak J. Flow cytometric analysis of tumor-infiltrating lymphocytes in patients with renal cell carcinoma, Br. J. Urol., 80 (1997) 543–547.
McCune CS, O’Donnell RW, Marquis DM, and Sahasrabudhe DM. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells, Cancer Immunol. Immunother., 32 (1990) 62–66.
Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, et al. A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinama, J. Immunother. Emphas. Tumor Immunol., 19 (1996) 364–374.
Galligioni E, Quaia M, Carbone A, Spada A, Favaro D, Santarosa M, et al. Adjuvant immunotherapy treatment of renal cell carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized trial, Cancer, 77 (1996) 2560–2566.
Logan TF, Banner B, Rao U, Ernstoff MS, Wolmark N, Whiteside TL, et al. Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy, Clin. Exp. Immunol., 114 (1998) 347–354.
Hawkins MJ. Interleukin-2 antitumor and effector cell responses, Semin. Oncol., 20 (1993) 52–59.
Figlin RA, Pierce WC, Kaboo R, Tso CL, Moldawer N, Gitlitz B, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8+ selected tumor infiltrating lymphocytes from primary tumor, J. Urol., 158 (1997) 740–745.
Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, and Shu S. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti- CD3 and interleukin2, J. Clin. Oncol., 15 (1997) 796–807.
Goodegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M, and Eberlein TJ. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study, J. Clin. Oncol., 13 (1995) 1939–1949.
Seliger B, Hohne A, Knuth A, Bernhard H, Meyer T, Tampe R, et al. Analysis of major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression, Cancer Res., 56 (1996) 1756–1760.
Kolbeck PC, Kaveggia FF, Johansson SL, Grune MT, and Taylor RJ. The relationships among tumor-infiltrating lymphocytes, histopathologic findings, and long-term clinical follow-up in renal cell carcinoma, Mod. Pathol., 5 (1992) 420–425.
Storkel S, Keymer R, Steinbach F, and Thoenes W. Reaction pattern of tumor infiltrating lymphocytes in different renal cell carcinomas and oncocytomas, Prog. Clin. Biol. Res., 378 (1992) 217–223.
Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, and Coffman RL. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins, J. Immunol., 136 (1986) 2348–2357.
Lucey DR, Clerici M, and Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflmamatory diseases, Clin. Microbiol. Rev., 9 (1996) 532–562.
Mosmann TR, Li L, Hengartner H, Kagi D, Fu W, and Sad S. Differentiation and functions of T cell subsets, Ciba Found. Sym., 204 (1997) 148–154.
Gately MK, Gubler U, Brunda MJ, Nadeau RR, Anderson TD, Lipman JM, and Sarmiento U. Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases, Ther. Immunol., 1 (1994) 187–196.
O’Garra A, Hosken N, Macatonia S, Wenner CA, and Murphy K. The role of macrophage-and dendritic cell-derived IL-12 in Th1 phenotype development, Res. Immunol., 146 (1995) 466–472.
Trinchieri G. Role of IL-12 in human Th1 response, Chem. Immunol., 63 (1996) 14–29.
Hussell T, Khan U, and Openshaw P. IL-12 treatment attentuates T helper type 2 and B cell responses but does not improve vaccine-enhanced lung illness, J. Immunol., 159 (1997) 328–334.
Scott P, Hondowicz B, Eatron A, and Scharton-Kersten T. The role of IL-12 in regulation of T helper cell subsets in vivo. Lessons from experimental cutaneous leishmaniasis, Ann NY Acad. Sci., 795 (1996) 250–256.
Knoefel B, Nuske K, Steiner T, Junker K, Kosmehl H, Rebstock K, et al. Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-b1 in primary cultures and modulate T lymphocyte blast transformation, J. Interferon Cytokine Res., 17 (1997) 95–102.
Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma, Cancer Res., 52 (1992) 3317–3322.
Cousens LP, Orange JS, Su HC, and Biron CA. Interferon-a/ß inhibition of interleukin 12 and interferon-y production in vitro and endogenously during viral infection, Proc. Natl. Acad. Sci. USA, 94 (1997) 634–639.
Ulchaker J, Panuto J, Rayman P, Novick A, Elson P, Tubbs R, et al. Interferon-y production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12, J. Immunoth., 22 (1999) 71–79.
Maeurer MJ, Martin DM, Castelli C, Elder E, Leder G, Storkus WJ, and Lotze MT. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes, Cancer Immunol. Immunother., 41 (1995) 111–121.
Schoof DD, Terashima Y, Peoples GE, Goedegebuure PS, Andrews JV, Richie JP, and Eberlein TJ. CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells, Cell. Immunol., 150 (1993) 114–123.
Goldman M and Druet P. The Th1/Th2 concept and its relevance to renal disorders and transplantation immunity, Neprol. Dial. Transplant., 10 (1995) 1282–1284.
Elsasser-Beile U, Kolble N, Grussenmeyer T, Schultze-Seemann W, Wetterauer U, Gallati H, et al. Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas, Tumour Biol., 19 (1998) 470–476.
Fridman WH and Tartour E. Macrophage-and lymphocyte-produced Th1 and Th2 cytokines in the tumour microenvironment, Res. Immunol., 149 (1998) 651–653.
Onishi T, Ohishi Y, Imagawa K, Ohmoto Y, and Murata K. An assessment of the immunological environment based on intratumoral cytokine production in renal cell carcinoma, BJU Int., 83 (1999) 488–492.
Furihata M, Ohtsuki Y, Sonobe H, Araki K, Ogata T, Toki T, et al. Prognostic significance of simultaneous infiltration of HLA-DR-positive dendritic cells and tumor infiltrating lymphocytes into human esophageal carcinoma, Tohoku J. Exp. Med., 169 (1993) 187–195.
Tsujitani S, Kukeji Y, Maehara Y, Sugimachi K, and Kaibara N. Dendritic cells prevent lymph node metastasis in patient with gastric cancer, In Vivo, 7 (1993) 233–237.
Kerrebijn JD, Balm AJ, Knegt PP, Meeuwis CA, and Drexhage HA. Macrophage and dendritic cell infiltration in head and neck squamous-cell carcinoma; an immunohistochemical study, Cancer Immunol. Immunother., 38 (1994) 31–37.
Zeid NA and Muller HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival, Pathol., 25 (1993) 338–343.
Young JW and Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity, J. Exp. Med., 183 (1996) 7–11.
Troy AJ, Summers KL, Davidson PJ, Atkinson CH, and Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma, Clin. Cancer Res., 4 (1998) 585–593.
Thurnher M, Radmayr C, Ramoner R, Ebner S, Bock G, Klocker H, et al. Human renal-cell carcinoma tissue contains dendritic cells, Int. J. Cancer, 68 (1996) 1–7.
Townsend ARM. Antigen recognition by class I-restricted T lymphocytes, Ann. Rev. Immunol., 7 (1989) 601–624.
Townsend ARM, Rothbard J, Gotch FM, Bahadur G, Wraith D, and McMichael AJ. The epitope of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides, Cell, 44 (1986) 959–968.
van der Bruggen P and Van den Eynde B. Molecular definition of tumor antigens recognized by T lymphocytes, Curr. Opin. Immunol., 4 (1992) 608–612.
Engelhard VH. Structure of peptides associated with MHC class I and class II molecules, Ann. Rev. Immunol., 12 (1994) 181–207.
Rammensee H-G. Chemistry of peptides associated with MHC class I and II molecules, Curr. Opin. Immunol., 7 (1995) 85–96.
Monaco JJ. A molecular model of MHC class I-restricted antigen processing, Immunol. Today, 13 (1992) 173–179.
Cresswell P. Antigen processing, Ann. Rev. Immunol., 11 (1993) 259–293.
Falk K, Roetschke O, Stevanovic S, Jung G, and Rammensee HG. Allele specific motifs revealed by sequencing of self peptides eluted from MHC molecules, Nature, 351 (1991) 290–296.
Kubo RT, Sette A, Grey HM, Appella E, Sakeguchi K, Zhu N-Z, et al. Definition of specific peptide motifs for four major HLA-A alleles, J. Immunol., 152 (1994) 3913–3924.
Falk K and Rotzschke O. Consensus motifs and peptide ligands of MHC class I molecules, Sem. Immunol., 5 (1993) 81–89.
Pamer EG, Harty JT, and Bevan MJ. Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes, Nature, 353 (1991) 852–855.
van der Burg AH, Visseren MJW, Brandt RMP, Kast WM, and Melief CJM. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability, J. Immunol., 156 (1996) 3308–3314.
Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes, J. Immunol., 153 (1994) 5586–5592.
van Elsas A, van der Berg SH, van der Minne CE, Borghi M, Mourer JS, Melief CJM, and Schrier PI. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*020 1 -binding peptides from the Melan-A/MART-1 self antigen, Eur. J. Immunol., 26 (1996) 1683–1689.
Wang W, Gulden PH, Pierce RA, Shabanowitz JA, Man ST, Hunt DF, and Engelhard VH. A naturally processed peptide presented by HLA-A*0201 is expressed at low abundance and recognized by an alloreactive CD8+ cytotoxic T cell with apparent high affinity, J. Immunol., 158 (1997) 5797–5804.
Sykulev Y, Cohen RJ, and Eisen HN. The law of mass action governs antigen-stimulated cytolytic activity of CD8+ cytotoxic T lymphocytes, Proc. Natl. Acad. Sci. USA, 92 (1995) 11,990–11,992.
Harding CV and Unanue ER. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation, Nature, 346 (1990) 574–576.
Jung D, Jaeger E, Cayeux S, Blankenstein T, Hilmes C, Karbach J, et al. Strong immunogenic potential of a B7 retroviral expression vector: generation of HLA-B7-restricted CTL response against selectable marker genes, Hum. Gene Ther., 9 (1998) 53–62.
Itoh K, Umezu Y, Morita T, Saya H, Seito D, Augustus LB, et al. Increase in the capability of interleukin 2 gene-transduced renal cell carcinoma cells to induce cytotoxic lymphocytes, Kurume Med. J., 41 (1994) 53–63.
Wang YC, Zhu L, McHugh R, Graham SD Jr, Hillyer CD, Dillehay D, et al. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7–1 (CD80) costimulation, J. Immother. Emphasis Tumor Immunol., 19 (1996) 1–8.
Meyer GC, Moebius U, Rudy W, Batrla R, Meuer SC, Wallwiener D, and Guckel B. Induction of antigen-specific T cells by allogeneic CD80 transfected human carcinoma cells, Adv. Exp. Med. Biol., 451 (1998) 195–202.
Mulders P, Tso CL, Pand S, Kaboo R, McBride WH, Hinkel A, et al. Adenovirus-mediated interleukin2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma, J. Immunother., 21 (1998) 170–180.
Finke JH, Rayman P, Edinger M, Tubbs RR, Stanley J, Klein E, and Bukowski R. Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line, J. Immunother., 11 (1992) 1–11.
Schendel DJ, Gansbacher B, Oberneder R, Kreigmair M, Hofstetter A, Reithmuller G, and Segurado OG. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines, J. Immunol., 151 (1993) 4209–4220.
Bernhard H, Maeurer MJ, Jager E, Wolfel T, Schneider J, Karbach J, et al. Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-y, Scand. J. Immunol., 44 (1996) 285–292.
Bernhard H, Jager E, Maeurer MJ, Meyer zum Buschenfelde KH, and Knuth A. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes, Tissue Antigens, 48 (1996) 22–31.
Brouwenstijn N, Gaugler B, Kruse KM, van der Speck CW, Mulder A, Osanto S, et al. Renal-cell carcinoma-specific lysis by cytotoxic T -lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes, Int. J. Cancer, 68 (1996) 177–182.
Brouwenstijn N, Hoogstraten C, Verdegaal EM, Van der Spek CW, Deckers JG, Mulder A, et al. Definition of unique and shared T-cell defined tumor antigens in human renal cell carcinoma, J. Immunother., 21 (1998) 427–434.
Topalian SL. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy, Curr. Opin. Immunol., 6 (1994) 741–745.
Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity, 2 (1995) 167–175.
Ronsin C, Chung-Scott V, Poullion I, Aknouche N, Gaudin C, and Triebel F. A non-AUG- defined alternate open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ, J. Immunol., 163 (1999) 483–490.
Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, and Rosenberg SA. A mutated ß-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes, J. Exp. Med., 183 (1996) 1185–1192.
Neumann E, Engelberg A, Decker J, Storkel S, Jaeger E, Huber C, and Seliger B. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res., 58 (1998) 4090–4095.
Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma, Science, 269 (1995) 1281–1284.
van den Eynde B, Peeters O, De Backer O, Baugler B, Lucas S, and Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma, J. Exp. Med., 182 (1995) 689–698.
Wang R, Robbins PF, Kawakami Y, Kang X, and Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes, J. Exp. Med., 181 (1995) 799–804.
Cox AL, Skipper J, Chien Y, Henderson RA, Darrow TL, Shabinowitz J, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines, Science, 264 (1994) 716–719.
Bakker AB, Schreurs MW, Tafazzul G, de Boer AJ, Kawakami Y, Adema GJ, and Figdor CG. Identification of a novel peptide derived from the melanocyte-specific gp 100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line, Int. J. Cancer, 62 (1995) 97–102.
Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression, J. Immunol., 154 (1995) 3961–3968.
Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, and Brugger W. Her-2/neuderived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes, Cancer Res., 58 (1998) 732–736.
Zhang XH, Takenaka I, Sato C, and Sakamoto H. p53 and Her-2 alterations in renal cell carcinoma, Urology, 50 (1997) 636–642.
Selli C, Amorosi A, Vona G, Sestini R, Travaglini F, Bartoletti R, and Orlando C. Retrospective evaluation of c-erbB-2 oncogene amplification using competetive PCR in collecting duct carcinoma of the kidney, J. Urol., 158 (1997) 245–247.
Guadin C, Kremer F, Angevin E, Scott V, and Triebel F. A hsp70–2 mutation recognized by CTL on a human renal cell carcinoma, J. Immunol., 162 (1999) 1730–1738.
van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, 254 (1991) 1643–1647.
Traversai C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E, J. Exp. Med., 176 (1992) 1453–1457.
van der Bruggen P, Szikora JP, Boel P, Wildmann C, Somville M, Sensi M, and Boon T. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601, Eur. J. Immunol., 24 (1994) 2134–2140.
Gaugler B, van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, et al. Human gene MAGE-3 codes for an antigen recognized on a human melanoma by autologous cytolytic T lymphocytes, J. Exp. Med., 179 (1994) 921–930.
van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3, Eur. J. Immunol., 24 (1994) 3038–3043.
Herman J, van der Bruggen P, Luescher IF, Mandruzzato S, Romero P, Thonnard J, et al. A peptide encoded by the human MAGE-3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3, Immunogenetics, 43 (1996) 377–383.
Coulie PG, Brichard V, van Pel A, Wolfel T, Schneider J, Traversari C, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas, J. Exp. Med., 180 (1994) 35–42.
Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor, Proc. Natl. Acad. Sci. USA, 91 (1994) 3515–3519.
Castelli C, Storkus WJ, Maeurer MJ, Huang E, Pramanik B, and Lotze MT. Mass spectrometric identification of a naturally-processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes, J. Exp. Med., 181 (1995) 363–366.
Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes, J. Exp. Med., 180 (1994) 347–352.
Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichart VL, Stevanovic S, et al. Identification of HLAA2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies, Blood, 93 (1999) 4309–4317.
Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, and Boon T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma, Proc. Natl. Acad. Sci. USA, 92 (1995) 7976–7980.
Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, et al. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene, J. Exp. Med., 183 (1996) 1173–1183.
Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening, Proc. Natl. Acad. Sci. USA, 94 (1997) 1914–1918.
Chen YT, Gure AO, Tsang S, Stockert E, Jager E, Knuth A, and Old LJ. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library, Proc. Natl. Acad. Sci. USA, 95 (1998) 6919–6923.
Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, et al. Simultaneous humoral and cellular immune response against cancer-testis NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes, J. Exp. Med., 187 (1998) 265–270.
Robbins PF, El-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes, J. Immunol., 154 (1995) 5944–5450.
Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor, Immunity, 6 (1997) 199–208.
Van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukemia cells, Br. J. Haetmatol., 102 (1998) 1376–1379.
Guagler B, Brouwenstijn N, Vantomme V, Szikora JP, Van der Speck CW, Patard JJ, et al. A new gene coding for and antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma, Immunogenetics, 44 (1996) 323–330.
Flad T, Spengler B, Kalbacher H, Brossart P, Baier D, Kaufmann R, et al. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method, Cancer Res., 58 (1999) 5803–5811.
Van den Eynde B and Brichard VG. New tumor antigens recognized by T cells, Curr. Opin. Immunol., 7 (1995) 674–681.
Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde K-H, and Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes, Eur. J. Immunol., 24 (1994) 759–764.
Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas, J. Exp. Med., 178 (1993) 489–495.
Skipper JCA, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, et al. An HLA-A2- restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins, J. Exp. Med., 183 (1996) 527–534.
Brichard VG, Herman J, van Pel A, Wildmann C, Gaugler B, Wolfel T, et al. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes, Eur. J. Immunol., 26 (1996) 224–230.
Steffens MG, Oosterwijk-Wakka JC, Zegwaart-Hagemeier NE, Boerman OC, Debruyne FM, Corstens FH, and Oosterwijk E. Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250, Anticancer Res., 19 (1999) 1197–2000.
Herr W, Protzer U, Lohse AW, Gerken G, Meyer zum Buschenfelde KH, and Wolfel T J. Quantification of CD8+ T lymphocytes responsive to human immunodeficiency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure, Infect. Dis., 178 (1998) 260–265.
Herr W, Linn B, Leister N, Wandel E, Meyer zum Buschenfelde KH, and Wolfel TJ. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens, Immunol. Methods, 203 (1997) 141–152.
Herr W, Ranieri E, Gambotto A, Kierstead LS, Amoscato AA, Gesualdo L, and Storkus WJ. Identification of naturally-processed HLA-presented Epstein-Barr virus peptides recognized by ex vivo CD4+ or CD8+ T lymphocytes from human blood. Submitted for publication, 1999.
Hernberg M, Mubonen T, and Pyrhonen S. Can the CD4+/CD8+ ratio predict the outcome of inteferoná therapy? Ann. Ocol., 8 (1997) 71–77.
Alexander RB, Fitzgerald EB, Mixon A, Carter CS, Jakobsen M, Cohen PA, and Rosenberg SA. Helper T cells infiltrating human renal cell carcinomas have the phenotype of activated memory-like T lymphocytes, J. Immunother. Emphasis Tumor Immunol., 17 (1995) 39–46.
Ozdemir E, Kakehi Y, Nakamura E, Kinoshita H, Terachi T, Okada Y, and Yoshida O. HLADRB1*0101 and *0405 as protective alleles in Japanese patients with renal cell carcinoma, Cancer Res., 57 (1997) 742–746.
Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, and Rosenberg SA. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene, Proc. Natl. Acad. Sci. USA, 91 (1994) 9461–9565.
Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kun L, and Kalbacher H. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3, Cancer Res., 57 (1997) 3238–3244.
Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, et al. Identification of MAGE-3 epitopes presented by HLA-DR moleules to CD4(+) T lymphocytes, J. Exp. Med., 189 (1999) 767–778.
Heicappell R and Ackermann R. Renal carcinoma (RC): regulation of antitumoral immune responses, Prog. Clin. Biol. Res., 378 (1992) 207–216.
Godley PA and Escobar MA. Renal cell carcinoma, Curr. Opin. Oncol., 10 (1998) 261–265.
Stadler WM, Kuzel T, Dumas M, and Vogelzang NJ. Multicenter phase II trial of interleukin-2, interferon-a, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinaoma, J. Clin. Oncol., 16 (1998) 1820–1825.
Rini BI, Stadler WM, Spielberger RT, Ratain MJ, and Vogelzang NJ. Granulocyte-macrophagecolony stimulating factor in metastatic renal cell carcinoma: a phase II trial, Cancer, 82 (1998) 1352–1358.
Franklin JR, Figlin R, and Belldegrun A. Renal cell carcinoma: basic biology and clinical behavior, Semin. Urol. Oncol., 14 (1996) 208–215.
Bono AV and Lovisolo JA. Renal cell carcinoma-diagnosis and treatment: state of the art, Eur. Urol., 31S (1997) 47–55.
Maeurer M, Storkus WJ, and Lotze MT. Cancer vaccines. In Clinical Immunology. Principles and practice. Volume II. Rich RR, Fleisher TA, Schwartz BD, Shearer WT, and Strober W (eds.), Mosby, Philadelphia, PA, 1995, pp. 1904–1918.
Walker C. Molecular genetics of renal carcinogenesis, Toxicol. Pathol., 26 (1998) 113–120.
Storkus WJ and Lotze MT. Tumor antigens recognized by immune cells. In Biologic Therapy of Cancer. DeVita VT, Hellmann S, and Rosenberg SA (eds.), 2nd ed, JB Lippincott, Philadelphia, PA, 1995, pp. 64–77.
Boon T and van der Bruggen P. Human tumor antigens recognized by T lymphocytes, J. Exp. Med., 183 (1996) 725–729.
Maeurer MJ, Gollin SM, Storkus WJ, Swaney W, Martin DM, Castelli C, et al. Tumor escape from immune recognition. I. Loss of HLA-A2 melanoma cell surface expression associated with a complex rearrangement of the short arm of chromosome 6, Clin. Cancer Res., 2 (1996) 641–652.
Maeurer MJ, Gollin SM, Martin DM, Swaney W, Bryant J, Castelli C, et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/MelanA antigen, J. Clin. Inv., 98 (1996) 1633–1642.
Keene JA and Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes, J. Exp. Med., 155 (1982) 768.
Ossendorp F, Mengede E, Camps M, Filius R, and Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex II negative tumors, J. Exp. Med., 187 (1998) 693–702.
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells, Nature Med., 4 (1998) 328–332.
Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells, Nature Med., 2 (1996) 52–55.
Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease, Prostate, 38 (1999) 73–78.
Albert ML, Sauter B, and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs, Nature, 392 (1998) 86–89.
Umezu Y, Augustus LB, Seito D, Hayakawa K, Ross MI, Eton O, et al. Increase in the ability of human cancer cells to induce cytotoxic T lymphocytes by ultraviolet irradiation, Cancer Immunol. Immunother., 37 (1993) 392–399.
Vanderlugt CJ and Miller SD. Epitope spreading, Curr. Opin. Immunol., 8 (1996) 831–836.
Celluzzi CM and Falo LD Jr. Epidermal dendrtici cells induce potent antigen-specific CTL- mediated immunity, J. Invest. Dermatol., 108 (1997) 716–720.
Disis ML, Grabstein KH, Sleath PR, and Cheever MA. Generation of immunity to Her- 2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine, Clin. Cancer Res., 5 (1999) 1289–1297.
Mulders P, Tso CL, Gitlitz B, Kaboo R, Hinkel A, Frand S, et al. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines, Clin. Cancer Res., 5 (1999) 445–454.
Thurner M, Rieser C, Holtl L, Papesh C, Ramoner R, and Bartsch G. Dendritic cell-based immunotherapy of renal cell carcinoma, Urol. Int., 61 (1998) 67–71.
Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells, J. Urol., 161 (1999) 777–782.
Holtl L, Rieser C, Papesh C, Ramoner R, Bartsch G, and Thurnher M. CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer, Lancet, 352 (1998) 1358.
Pardoll DM. Inducing autoimmune disease to treat cancer, Proc. Natl. Acad. Sci. USA, 96 (1999) 5340–5342.
Franzke A, Peete D, Probst-Kepper M, Buer J, Kirchner GI, Brabant G, et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer, J. Clin. Oncol., 17 (1999) 529–533.
Horie S, Kano M, Higashihara E, Moriyama N, Tanaka E, Hirose A, et al. Expression of Fas in renal cell carcinoma, Jpn. J. Clin. Oncol., 27 (1997) 384–388.
Uzzo RG, Rayman P, Kolenko V, Clark PE, Bloom T, Ward AM, et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma, Clin. Cancer Res., 5 (1999) 1219–1229.
Pai TF, Silva RA, Smedegaard B, Appelberg R, and Andersen P. Analysis of T cells recruited during delayed-type hypersensitivity to purified protein derivative (PPD) versus challenge with tuberculosis infection, Immunology, 95 (1998) 69–75.
Buchanan KL and Murphy JW. Kinetics of cellular infiltration and cytokine production during the efferent phase of a delayed-type hypersensitivity reaction, Immunology, 90 (1997) 189–197.
Tannenbaum CS, Wicker N, Armstrong D, Tubbs R, Finke J, Bukowski RM, and Hamilton TA. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12, J. Immunol., 156 (1996) 693–699.
Lotze MT, Hellerstedt B, Stolinski L, Tueting T, Wilson C, Kinzler D, et al. The role of interleukin2, interleukin-12, and dendritic cells in cancer therapy, Cancer J. Sci. Am., 3 (1997) 5109–5114.
Dooms H, Desmedt M, Vancaeneghem S, Rottiers P, Goosens V, Fiers W, and Grooten J. Quiescence-inducing and antiapoptotic activities of IL-15 enhance secondary CD4+ T cell responsiveness to antigen, J. Immunol., 161 (1998) 2141–2150.
Estaquier J, Idziorek T, Zou W, Emilie D, Farber CM, Bourez JM, and Ameisen JC. T helper type 1/ T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons, J. Exp. Med., 182 (1995) 1759–1767.
Macatonia SE, Hosken NA, Litton M, Viera P, Hsieh CS, Culpepper JA, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells, J. Immunol., 154 (1995) 5071–5079.
Belardelli F and Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use, Immunol. Today, 17 (1996) 369–372.
Kohyama M, Saijyo K, Hayasida M, Yasugi T, Kurimoto M, and Ono T. Direct activation of human CD8+ cytotoxic T lymphocytes by interleukin-18, Jpn. J. Cancer Res., 89 (1998) 1041–1046.
Wenner CA, Guler ML, Macatonia SE, O’Garra A, and Murphy KM. Roles of IFN-y and IFN-a in IL-12-induced T helper cell-1 development, J. Immunol., 156 (1996) 1442–1447.
Alijagic S, Moller P, Artuc M, Jurgovsky K, Czarnetzki BM, and Schadendorf D. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation, Eur. J. Immunol., 25 (1995) 3100–3107.
Tueting T, Wilson CC, Martin DM, Kasamon Y, Rowles J, Ma DI, et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-a, J. Immunol., 160 (1998) 1139–1147.
Wilson CC, Olson WC, Tueting T, Rinaldo CR, Lotze MT, and Storkus WJ. HIV-1- specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines, J. Immunol., 162 (1999) 3070–3078.
Zitvogel L, Couderc B, Mayordomo JI, Robbins PD, Lotze MT, and Storkus WJ. IL-12 engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo, Ann. NY Acad. Sci., 795 (1996) 284–293.
Dieu MC, Vanderliet B, Vicari A, Bridon JM, Oldham E, Ait-Yahier S, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites, J. Exp. Med., 199 (1998) 373–386.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Finke, J.H., Kierstead, L.S., Ranieri, E., Storkus, W.J. (2000). Immunologic Response to Renal Cell Carcinoma. In: Bukowski, R.M., Novick, A.C. (eds) Renal Cell Carcinoma. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-229-6_3
Download citation
DOI: https://doi.org/10.1007/978-1-59259-229-6_3
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-6401-7
Online ISBN: 978-1-59259-229-6
eBook Packages: Springer Book Archive